Paloma Partners’s Altimmune ALT Stock Holding History

Paloma Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-780	Closed	-$75K	–	2065
2017 Q2	$75K	Buy	+780	New	+$130K	﹤0.01%	2093

Other funds holding ALT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Paloma Partners's ALT Position: Q3 2017 in Review

Paloma Partners sold out of Altimmune (ALT) in Q3 2017, closing a stake of 780 shares — an estimated $75K sold.

Paloma Partners first reported a position in ALT in Q2 2017 and held it in 1 quarter. The position peaked at $75K in Q2 2017. 29 funds tracked by Wall St. Rank hold ALT as of Q3 2017.

Paloma Partners reported no remaining Altimmune position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 780 Altimmune shares in Q3 2017, an estimated $75K.
Paloma Partners first reported a position in Altimmune in Q2 2017 and held it in 1 quarter.
Paloma Partners's Altimmune position peaked at $75K in Q2 2017.
29 funds tracked by Wall St. Rank held Altimmune as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.